Close Menu

NEW YORK – The GenomeWeb Index rose more than 9 percent in May as investors continued to reward companies' efforts to develop new diagnostics for the SARS-CoV-2 virus, as well as positive earnings reports.

The index also outperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, which rose 4 percent, 7 percent, and 8 percent, respectively. Individual stock performances in the GenomeWeb Index were largely positive in May, as 24 of the 32 stocks saw gains and just eight saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.